ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2025, Vol. 34 ›› Issue (2): 195-200.DOI: 10.3969/j.issn.1006-298X.2025.02.019

• 临床集锦 • 上一篇    

奥妥珠单抗成功治疗利妥昔单抗抵抗磷脂酶A2受体相关膜性肾病

  

  • 出版日期:2025-04-28 发布日期:2025-05-07

Rituximab-resistant phospholipase A2 receptor associated membranous nephropathy successfully treated with Obinutuzumab

  • Online:2025-04-28 Published:2025-05-07

摘要: 中年男性患者,肾病综合征起病,肾活检诊断磷脂酶A2受体(PLA2R)相关膜性肾病,激素联合他克莫司治疗无效。改用利妥昔单抗1 g×2次诱导,3月后B细胞重建,血抗PLA2R抗体(aPLA2Rab)反弹,血清肌酐(SCr)进一步升高。重复肾活检见局灶节段性肾小球硬化,肾小管间质损伤加重,上皮侧免疫复合物沉积增多,诊断PLA2R相关膜性肾病伴急性肾小管间质损伤,调整为奥妥珠单抗1 g×2次,6月后追加1 g维持,随访14.5月,外周血B细胞持续清零,血aPLA2Rab转阴,SCr由185.6 μmol/L降至103.4 μmol/L,尿蛋白定量从14.12 g/24h降至0.68 g/24h,持续部分缓解。


关键词: 膜性肾病, 利妥昔单抗, 奥妥珠单抗

Abstract: A 53-year-old male presented with nephrotic syndrome was diagnosed as phospholipase A2 receptor (PLA2R) associated membranous nephropathy (MN) by renal biopsy. Initial immunosuppressive regimen was steroid plus tacrolimus but no remission was achieved. Then the patient received standard dose Rituximab (1g×2) treatment. But B cell reconstituted at the third months following RTX administration, accompanied with anti-PLA2R antibody (aPLA2Rab) rebounded, proteinuria aggravation and serum creatinine increase. Repeated renal biopsy revealed focal segmental glomerulosclerosis, tubulointerstitial injury aggravation and immune complex deposition increase. The diagnosis of PLA2R associated MN, acute renal tubulointerstitial injury was established. Obinutuzumab 1g×2 was used for induction and the third dose was given at month 6 for maintain. At last visit (14.5 months following Obinutuzumab treatment), serum creatine declined from 185.6 μmol/L to 103.4 μmol/L, proteinuria declined from 14.12 g/24h to 0.68 g/24h, aPLA2Rab remained negative and B cell remained depletion.


Key words: membranous nephropathy, Rituximab, Obinutuzumab